Journal article 506 views 35 downloads
Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology
Oxford Open Immunology, Volume: 1, Issue: 1
Swansea University Author:
Luke Davies
-
PDF | Version of Record
Copyright: The Author(s) 2020. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.
Download (738.54KB)
DOI (Published version): 10.1093/oxfimm/iqaa005
Abstract
The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a global health crisis and will likely continue to impact public health for years. As the effectiveness of the innate immune response is crucial to patient outcome...
Published in: | Oxford Open Immunology |
---|---|
ISSN: | 2633-6960 |
Published: |
Oxford University Press (OUP)
2020
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa61696 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
first_indexed |
2022-11-07T14:19:16Z |
---|---|
last_indexed |
2023-01-13T19:22:37Z |
id |
cronfa61696 |
recordtype |
SURis |
fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2022-11-07T14:21:11.2120226</datestamp><bib-version>v2</bib-version><id>61696</id><entry>2022-10-31</entry><title>Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology</title><swanseaauthors><author><sid>ff080296775381560053d5e3a6e81745</sid><ORCID>0000-0001-7767-4060</ORCID><firstname>Luke</firstname><surname>Davies</surname><name>Luke Davies</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-10-31</date><deptcode>BMS</deptcode><abstract>The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a global health crisis and will likely continue to impact public health for years. As the effectiveness of the innate immune response is crucial to patient outcome, huge efforts have been made to understand how dysregulated immune responses may contribute to disease progression. Here we have reviewed current knowledge of cellular innate immune responses to SARS-CoV-2 infection, highlighting areas for further investigation and suggesting potential strategies for intervention. We conclude that in severe COVID-19 initial innate responses, primarily type I interferon, are suppressed or sabotaged which results in an early interleukin (IL)-6, IL-10 and IL-1β-enhanced hyperinflammation. This inflammatory environment is driven by aberrant function of innate immune cells: monocytes, macrophages and natural killer cells dispersing viral pathogen-associated molecular patterns and damage-associated molecular patterns into tissues. This results in primarily neutrophil-driven pathology including fibrosis that causes acute respiratory distress syndrome. Activated leukocytes and neutrophil extracellular traps also promote immunothrombotic clots that embed into the lungs and kidneys of severe COVID-19 patients, are worsened by immobility in the intensive care unit and are perhaps responsible for the high mortality. Therefore, treatments that target inflammation and coagulation are promising strategies for reducing mortality in COVID-19.</abstract><type>Journal Article</type><journal>Oxford Open Immunology</journal><volume>1</volume><journalNumber>1</journalNumber><paginationStart/><paginationEnd/><publisher>Oxford University Press (OUP)</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2633-6960</issnElectronic><keywords>Innate immunology, COVID-19, Neutrophils, Monocytes, NK cells, Macrophages</keywords><publishedDay>8</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-12-08</publishedDate><doi>10.1093/oxfimm/iqaa005</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2022-11-07T14:21:11.2120226</lastEdited><Created>2022-10-31T12:37:27.2264405</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Patrícia R S</firstname><surname>Rodrigues</surname><order>1</order></author><author><firstname>Aljawharah</firstname><surname>Alrubayyi</surname><order>2</order></author><author><firstname>Ellie</firstname><surname>Pring</surname><order>3</order></author><author><firstname>Valentina M T</firstname><surname>Bart</surname><order>4</order></author><author><firstname>Ruth</firstname><surname>Jones</surname><order>5</order></author><author><firstname>Clarissa</firstname><surname>Coveney</surname><order>6</order></author><author><firstname>Fangfang</firstname><surname>Lu</surname><order>7</order></author><author><firstname>Michael</firstname><surname>Tellier</surname><orcid>0000-0002-4130-9050</orcid><order>8</order></author><author><firstname>Shayda</firstname><surname>Maleki-Toyserkani</surname><order>9</order></author><author><firstname>Felix C</firstname><surname>Richter</surname><orcid>0000-0002-3415-3449</orcid><order>10</order></author><author><firstname>D Oliver</firstname><surname>Scourfield</surname><order>11</order></author><author><firstname>Ester</firstname><surname>Gea-Mallorquí</surname><orcid>0000-0002-6915-074x</orcid><order>12</order></author><author><firstname>Luke</firstname><surname>Davies</surname><orcid>0000-0001-7767-4060</orcid><order>13</order></author></authors><documents><document><filename>61696__25672__35056fb3ee4c4345aea90fd7c8055ea5.pdf</filename><originalFilename>61696.pdf</originalFilename><uploaded>2022-11-07T14:20:03.0589485</uploaded><type>Output</type><contentLength>756270</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Copyright: The Author(s) 2020. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
spelling |
2022-11-07T14:21:11.2120226 v2 61696 2022-10-31 Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology ff080296775381560053d5e3a6e81745 0000-0001-7767-4060 Luke Davies Luke Davies true false 2022-10-31 BMS The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a global health crisis and will likely continue to impact public health for years. As the effectiveness of the innate immune response is crucial to patient outcome, huge efforts have been made to understand how dysregulated immune responses may contribute to disease progression. Here we have reviewed current knowledge of cellular innate immune responses to SARS-CoV-2 infection, highlighting areas for further investigation and suggesting potential strategies for intervention. We conclude that in severe COVID-19 initial innate responses, primarily type I interferon, are suppressed or sabotaged which results in an early interleukin (IL)-6, IL-10 and IL-1β-enhanced hyperinflammation. This inflammatory environment is driven by aberrant function of innate immune cells: monocytes, macrophages and natural killer cells dispersing viral pathogen-associated molecular patterns and damage-associated molecular patterns into tissues. This results in primarily neutrophil-driven pathology including fibrosis that causes acute respiratory distress syndrome. Activated leukocytes and neutrophil extracellular traps also promote immunothrombotic clots that embed into the lungs and kidneys of severe COVID-19 patients, are worsened by immobility in the intensive care unit and are perhaps responsible for the high mortality. Therefore, treatments that target inflammation and coagulation are promising strategies for reducing mortality in COVID-19. Journal Article Oxford Open Immunology 1 1 Oxford University Press (OUP) 2633-6960 Innate immunology, COVID-19, Neutrophils, Monocytes, NK cells, Macrophages 8 12 2020 2020-12-08 10.1093/oxfimm/iqaa005 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2022-11-07T14:21:11.2120226 2022-10-31T12:37:27.2264405 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Patrícia R S Rodrigues 1 Aljawharah Alrubayyi 2 Ellie Pring 3 Valentina M T Bart 4 Ruth Jones 5 Clarissa Coveney 6 Fangfang Lu 7 Michael Tellier 0000-0002-4130-9050 8 Shayda Maleki-Toyserkani 9 Felix C Richter 0000-0002-3415-3449 10 D Oliver Scourfield 11 Ester Gea-Mallorquí 0000-0002-6915-074x 12 Luke Davies 0000-0001-7767-4060 13 61696__25672__35056fb3ee4c4345aea90fd7c8055ea5.pdf 61696.pdf 2022-11-07T14:20:03.0589485 Output 756270 application/pdf Version of Record true Copyright: The Author(s) 2020. This is an Open Access article distributed under the terms of the Creative Commons Attribution License. true eng http://creativecommons.org/licenses/by/4.0/ |
title |
Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology |
spellingShingle |
Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology Luke Davies |
title_short |
Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology |
title_full |
Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology |
title_fullStr |
Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology |
title_full_unstemmed |
Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology |
title_sort |
Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology |
author_id_str_mv |
ff080296775381560053d5e3a6e81745 |
author_id_fullname_str_mv |
ff080296775381560053d5e3a6e81745_***_Luke Davies |
author |
Luke Davies |
author2 |
Patrícia R S Rodrigues Aljawharah Alrubayyi Ellie Pring Valentina M T Bart Ruth Jones Clarissa Coveney Fangfang Lu Michael Tellier Shayda Maleki-Toyserkani Felix C Richter D Oliver Scourfield Ester Gea-Mallorquí Luke Davies |
format |
Journal article |
container_title |
Oxford Open Immunology |
container_volume |
1 |
container_issue |
1 |
publishDate |
2020 |
institution |
Swansea University |
issn |
2633-6960 |
doi_str_mv |
10.1093/oxfimm/iqaa005 |
publisher |
Oxford University Press (OUP) |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
document_store_str |
1 |
active_str |
0 |
description |
The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a global health crisis and will likely continue to impact public health for years. As the effectiveness of the innate immune response is crucial to patient outcome, huge efforts have been made to understand how dysregulated immune responses may contribute to disease progression. Here we have reviewed current knowledge of cellular innate immune responses to SARS-CoV-2 infection, highlighting areas for further investigation and suggesting potential strategies for intervention. We conclude that in severe COVID-19 initial innate responses, primarily type I interferon, are suppressed or sabotaged which results in an early interleukin (IL)-6, IL-10 and IL-1β-enhanced hyperinflammation. This inflammatory environment is driven by aberrant function of innate immune cells: monocytes, macrophages and natural killer cells dispersing viral pathogen-associated molecular patterns and damage-associated molecular patterns into tissues. This results in primarily neutrophil-driven pathology including fibrosis that causes acute respiratory distress syndrome. Activated leukocytes and neutrophil extracellular traps also promote immunothrombotic clots that embed into the lungs and kidneys of severe COVID-19 patients, are worsened by immobility in the intensive care unit and are perhaps responsible for the high mortality. Therefore, treatments that target inflammation and coagulation are promising strategies for reducing mortality in COVID-19. |
published_date |
2020-12-08T04:20:42Z |
_version_ |
1763754369511063552 |
score |
11.021648 |